XDNA Kelly CRISPR & Gene Editing Technology ETF

*Unless otherwise stated, data provided by FactSet.

XDNA Fund Description

XDNA tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology.

XDNA Factset Analytics Insight

XDNA provides vanilla exposure to a very niche segment of the healthcare sector. The fund is passively managed, tracking an index of firms listed in developed markets that are involved in the research and development of DNA modification technology and its applications. Eligible companies must meet investability requirements and should derive significant revenue or profit from business activities related to (i) CRISPR & gene editing technology, (ii) gene editing development solutions, and (iii) gene editing sequencing solutions. The index may include common stocks, REITs, depositary receipts, and preferred stocks of large-, mid-, and small-cap companies. The resulting portfolio holds a maximum of 60 constituents, weighted by market capitalization. The index reconstitutes and rebalances its portfolio on a quarterly basis.

PERFORMANCE [as of 09/29/22] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
XDNA -7.73% 11.79% -- -- -- -- --
XDNA (NAV) -7.20% 11.98% -- -- -- -- --
N/A -- -- -- -- -- -- --
MSCI World IMI / Pharmaceuticals Biotechnology & Life Sciences -IG -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

XDNA Summary Data

Kelly
01/12/22
Open-Ended Fund
0.78%
$5.15M
$259.45K
0.59%

XDNA Portfolio Data

$28.48B
-5.92
3.05
--
N/A
25

XDNA Index Data

N/A
Market Cap
Market Cap
MSCI World IMI / Pharmaceuticals Biotechnology & Life Sciences -IG

XDNA Portfolio Management

0.78%
--
--
--

XDNA Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

XDNA Fund Structure

Open-Ended Fund
No
No
-- / --
N/A
N/A
High
Daily

XDNA Factset Analytics Block Liquidity

As of 09/30/22
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of XDNA. XDNA is rated a N/A out of 5.

XDNA Tradability

19,879
$259.45K
4,489
$57.57K
0.59%
$0.07
0.51%
4.26% / -3.64%
None
96.69%
--
--
--
--
5
$11.62
N/A

XDNA Sector/Industry Breakdown


XDNA
Segment Benchmark
99.90%
--
0.15%
--
-0.06%
--

XDNA Top 10 Holdings[View All]

AbbVie, Inc. 5.01%
4.71%
67.80%

XDNA Countries


XDNA
Segment Benchmark
96.39%
--
2.29%
--
1.20%
--

XDNA Regions


XDNA
Segment Benchmark
96.39%
--
3.49%
--

XDNA Economic Development


XDNA
Segment Benchmark
99.88%
--
0.00%
--

XDNA Performance Statistics

--
--
--
--
--
MSCI World IMI / Pharmaceuticals Biotechnology & Life Sciences -IG

XDNA Benchmark Comparison Holdings

25
--
--
--

XDNA Benchmark Comparison Summary


XDNA
Segment Benchmark
25
--
$28.48B
--
-5.92
--
3.05
--
0.37%
--
High
--

XDNA Benchmark Comparison Market Cap Size


XDNA
Segment Benchmark
20.42%
--
32.31%
--
26.56%
--
11.03%
--